Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that improve a patient's immune response against tumors.
InvoTek, a research and development firm from Alma, has received a $175,000 federal grant for development of the "Quad Rider," a gear and braking device that helps people with disabilities safely operate a handcycle.
The Vault is an internal incubator for student entrepreneurs set inside what once was the underground vault of the former Federal Reserve Bank at Third and Louisiana streets in downtown Little Rock. The building now serves students in grades 9-12 as eStem High School.
The R&D 100 is a prestigious list of the world's top 100 tech-based product innovations included each year in R&D Magazine. The R&D 100 is known as the "Oscars of Innovation" and past award winners have included the flashcube, ATM, fax machine and HDTV.